Syndax Pharmaceuticals Inc (SNDX) stock
Close on Nov 17, 2026Market cap $821.53MP/E –Yield –
Earnings
Syndax Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Syndax Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 2, 2026after the close | $83.30M | +81.5% | -$0.55 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026during market hours | $72.80M | +91.6% | -$0.55 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026during market hours | $64.90M | +223.8% | -$0.48 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026during market hours | $68.70M | +792.2% | -$0.78 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025during market hours | $45.90M | +267.2% | -$0.70 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025during market hours | $38.00M | +985.7% | -$0.83 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025during market hours | $20.04M | – | -$0.98 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 3, 2025before the open | $7.70M | – | -$1.10 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024during market hours | $12.50M | – | -$0.98 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024during market hours | $3.50M | – | -$0.80 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024before the open | – | – | -$0.85 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024during market hours | – | – | -$1.00 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | – | – | -$0.73 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023during market hours | – | – | -$0.64 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023during market hours | – | – | -$0.59 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023during market hours | – | – | -$0.62 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | – | – | -$0.58 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022during market hours | – | – | $0.62 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | – | – | -$0.63 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022during market hours | $126.60M | – | $1.81 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021during market hours | – | – | -$0.40 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 8, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 2, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Syndax Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total research and development plus selling, general and administrative expensesnon-GAAP | FY2026 | $400.00M | $400.00M | Reaffirmed | Nov 2, 2026 |
| total research and development plus selling, general and administrative expensesnon-GAAP | FY2026 | $400.00M | $400.00M | Reaffirmed | Aug 4, 2026 |
Guidance history
Every forecast Syndax Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 2, 2026 | total research and development plus selling, general and administrative expenses | FY2026 | $400.00M | Reaffirmed |
| Aug 4, 2026 | total research and development plus selling, general and administrative expenses | FY2026 | $400.00M | Reaffirmed |
| Apr 30, 2026 | total research and development plus selling, general and administrative expenses | FY2026 | $400.00M | Reaffirmed |
| Feb 26, 2026 | total research and development plus selling, general and administrative expenses | FY2026 | $400.00M | New |
| Jan 12, 2026 | total research and development plus selling, general and administrative expenses | FY2026 | $400.00M | New |
| Nov 3, 2025 | total research and development plus selling, general and administrative expenses | FY2025 | $380.00M – $385.00M | New |
| Aug 4, 2025 | total research and development plus selling, general and administrative expenses | Q3 FY2025 | $95.00M – $100.00M | New |
| Aug 4, 2025 | total research and development plus selling, general and administrative expenses | FY2025 | $370.00M – $390.00M | New |
| May 5, 2025 | research and development expenses | Q2 FY2025 | $70.00M – $75.00M | New |
| May 5, 2025 | total research and development plus selling, general and administrative expenses | Q2 FY2025 | $110.00M – $115.00M | Raised |
| May 5, 2025 | research and development expenses | FY2025 | $260.00M – $280.00M | Lowered |
| May 5, 2025 | total research and development plus selling, general and administrative expenses | FY2025 | $415.00M – $435.00M | Raised |
| Mar 3, 2025 | research and development expenses | Q1 FY2025 | $65.00M – $70.00M | New |
| Mar 3, 2025 | total research and development plus selling, general and administrative expenses | Q1 FY2025 | $105.00M – $110.00M | Raised |
| Mar 3, 2025 | research and development expenses | FY2025 | $260.00M – $280.00M | New |
| Mar 3, 2025 | total research and development plus selling, general and administrative expenses | FY2025 | $415.00M – $435.00M | Raised |
| Nov 5, 2024 | research and development expenses | FY2024 | $245.00M – $250.00M | Raised |
| Nov 5, 2024 | total operating expenses | FY2024 | $365.00M – $370.00M | Raised |
| Nov 5, 2024 | non-cash stock compensation expense | FY2024 | $41.00M | Lowered |
| Aug 1, 2024 | research and development expenses | Q3 FY2024 | $70.00M – $75.00M | New |
| Aug 1, 2024 | total operating expenses | Q3 FY2024 | $105.00M – $110.00M | Raised |
| Aug 1, 2024 | research and development expenses | FY2024 | $240.00M – $260.00M | Raised |
| Aug 1, 2024 | total operating expenses | FY2024 | $355.00M – $375.00M | Raised |
| Aug 1, 2024 | non-cash stock compensation expense | FY2024 | $43.00M | Lowered |
| May 8, 2024 | research and development expenses | Q2 FY2024 | $50.00M – $55.00M | New |
| May 8, 2024 | total operating expenses | Q2 FY2024 | $80.00M – $85.00M | Raised |
| May 8, 2024 | research and development expenses | FY2024 | $240.00M – $260.00M | Raised |
| May 8, 2024 | total operating expenses | FY2024 | $355.00M – $375.00M | Raised |
| May 8, 2024 | non-cash stock compensation expense | FY2024 | $43.00M | Lowered |
| Feb 27, 2024 | research and development expenses | Q1 FY2024 | $56.00M – $62.00M | New |
| Feb 27, 2024 | total operating expenses | Q1 FY2024 | $82.00M – $88.00M | Raised |
| Feb 27, 2024 | research and development expenses | FY2024 | $240.00M – $260.00M | New |
| Feb 27, 2024 | total operating expenses | FY2024 | $355.00M – $375.00M | Raised |
| Feb 27, 2024 | non-cash stock compensation expense | FY2024 | $43.00M | Lowered |
| Nov 2, 2023 | research and development expenses | FY2023 | $160.00M – $165.00M | Lowered |
| Nov 2, 2023 | total operating expenses | FY2023 | $225.00M – $230.00M | Raised |
| Aug 3, 2023 | research and development expenses | Q3 FY2023 | $39.00M – $43.00M | New |
| Aug 3, 2023 | total operating expenses | Q3 FY2023 | $57.00M – $62.00M | Raised |
| Aug 3, 2023 | research and development expenses | FY2023 | $160.00M – $175.00M | Lowered |
| Aug 3, 2023 | total operating expenses | FY2023 | $225.00M – $240.00M | Raised |
| May 8, 2023 | research and development expenses | Q2 FY2023 | $38.00M – $43.00M | New |
| May 8, 2023 | total operating expenses | Q2 FY2023 | $53.00M – $58.00M | Raised |
| May 8, 2023 | research and development expenses | FY2023 | $160.00M – $175.00M | Lowered |
| May 8, 2023 | total operating expenses | FY2023 | $225.00M – $240.00M | Raised |
| Feb 28, 2023 | research and development expenses | Q1 FY2023 | $30.00M – $35.00M | New |
| Feb 28, 2023 | total operating expenses | Q1 FY2023 | $40.00M – $45.00M | Raised |
| Feb 28, 2023 | research and development expenses | FY2023 | $160.00M – $175.00M | New |
| Feb 28, 2023 | total operating expenses | FY2023 | $225.00M – $240.00M | Raised |
| Nov 3, 2022 | research and development expenses | FY2022 | $115.00M – $125.00M | Lowered |
| Nov 3, 2022 | total operating expenses | FY2022 | $145.00M – $155.00M | Raised |
| Aug 8, 2022 | research and development expenses | Q3 FY2022 | $25.00M – $30.00M | New |
| Aug 8, 2022 | total operating expenses | Q3 FY2022 | $35.00M – $40.00M | Raised |
| Aug 8, 2022 | research and development expenses | FY2022 | $130.00M – $140.00M | Lowered |
| Aug 8, 2022 | total operating expenses | FY2022 | $160.00M – $170.00M | Raised |
| May 9, 2022 | research and development expenses | Q2 FY2022 | $30.00M – $35.00M | New |
| May 9, 2022 | total operating expenses | Q2 FY2022 | $38.00M – $42.00M | Raised |
| May 9, 2022 | research and development expenses | FY2022 | $130.00M – $140.00M | Lowered |
| May 9, 2022 | total operating expenses | FY2022 | $160.00M – $170.00M | Raised |
| Mar 1, 2022 | research and development expenses | Q1 FY2022 | $30.00M – $35.00M | New |
| Mar 1, 2022 | total operating expenses | Q1 FY2022 | $38.00M – $42.00M | Raised |
| Mar 1, 2022 | research and development expenses | FY2022 | $130.00M – $140.00M | New |
| Mar 1, 2022 | total operating expenses | FY2022 | $160.00M – $170.00M | Raised |
| Nov 15, 2021 | R&D expenses | FY2021 | $90.00M – $100.00M | New |
| Nov 15, 2021 | total operating expenses | FY2021 | $110.00M – $120.00M | Raised |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Syndax Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
See a number that looks wrong?